Following an inspiring video, Silvia Novello opened Lung Cancer Awareness day by framing @WalceOnlus2006 20-year journey through the lens of Odysseus's epic voyage, celebrating two decades of strength, hope, and commitment. #LungCancer #WALCE20 #OncoAlert

🔥Real-world tarlatamab in SCLC: ONWARD consortium, 11 US centers
🆙 @JTO @IASLC
🎯rw-PFS 2.3 mo, rw-OS 8.0 mo
🎯44.5% had brain mets; no PFS difference with vs without brain mets
🎯CRS 40.8% (G3-4 3.8%), ICANS 21.5% (G3-4 6%)
🎯Prophylactic tocilizumab: CRS 5.3% vs 43.0%
🎙Dr. an Zhang @sands_jacob @Sonampuri
#LCSM @OncoAlert @Larvol

Report @JTOonline showing tarlatamab efficacy in pts with atypical carcinoid (n=5, RR 60%, DCR 100%, mPFS 8.8m) and large cell neuroendocrine carcinoma (LCNEC, n=7, RR 43%, DCR 88%, mPFS 5.1m). DLL3 IHC potential predictive marker here.

jtocrr.org/article/S2666-…

#ESMO26 Today the thoracic oncology community celebrates:

🏆 The major advances in the fight against lung cancer reported at @myESMO

🎉The birthday of @JordiRemon 🥳 (great discussant!)

🐣 The new member of the lung cancer family on the way!!! ….and the best ever pregnant @DrJNaidoo

So happy to be part of this superfamily
May God bless you all and our patients

#ESMOAmbassadors

The lung cancer community at #ESMO26 Presidential Symposium III here for Dr. Jarushka Naidoo (+1) @DrJNaidoo - discussant on phase III trial of reduced frequency IO. One of the most brilliant minds in our field - always insightful, thoughtful, balanced. #ESMOAmbassadors @myESMO

#ESMO26 Presidential 1 :
#SCLC DeLLphi-305:
Who would have imagined some years ago that median OS of SCLC would equal that of non-AGA NSCLC!

#Tarlatamab as 1L maintenance with Durvalumab after induction chemoIO in ES-SCLC improved OS from 12.7 to an impressive 21.1m, f 0.42.
80% of patients alive and 38% progression-free at 12 months
The dawn of a new era for thoracic oncology and for the lives of our patients 💫✨
@myESMO @SclcSMASHERS
#ESMOAmbassadors

#ESMO26 : A great brainstorming summit on #SCLC organized by @LungSummit in a fully packed auditorium+overflow following yesterday’s announcement of DeLlphi-305;

➡️ The chemoIO landscape in 1L @MartinReck2
➡️ T-cell engager clinical development @peters_solange
➡️ Management οf zios
➡️ Sequencing and combinations @NReguart

A heartfelt 🙏 for your presence, interaction and tons of questions!!!
#ESMOAmbassadors

#ESMO26 Does Tarlatamab provide long term benefit to responding patients?

✅The answer is Yes!

➡️Extended F-UP of the Dellphi-304 trial shows that after 22m of F-UP Landmark 2-year OS was 30% vs 15% and sustained disease control in 24% of patients at > 52 weeks

❓We need to invstics of those patients to understand how we can improve the outcomes of the 70% of patients who do not make it to two years
@myESMO
#ESMOAmbassadors

#ESMO26 Presidential 1
Excellent state-of-the art discussion on #Dellphi-305 by the 1@only @StephenVLiu
emphasizing on:

➡️ 1L maintenance Tarla setting a new SoC with a mOS of>20 months
❓High attrition rate from induction to maintenance, need for earlier TCE ( Dellphi-312)
❌Onl arm received 2L Tarla post-progression reflecting access hurdles
✅ Global access to Tarla will make innovation meaningful for our patients
@@myESMO #ESMOAmbassadors

HUGE news. Perhaps one of the most important top line results for a common solid tumor. Looking forward to the data @OncoAlert

#SCLC therapeutic landscape is rapidly changing, with T-cell engagers, ADCs and bi-specifics moving fast to earlier lines of treatment and challenging the current treatment paradigm
Thrilled to discuss the landscape with KOLs @peters_solange and @nicogirardcurie in a ion
Follow the link below to access:
#some #LCSM @SclcSMASHERS
@LUNGevity @LungCancerEu

MCCR2026 at the start!! Another exciting workshop in clinical trial research. One protocol in one week!
@lillian_siu @drcmassard @BenjaminBesseMD @giannatempopatr @EORTC @myESMO @AACR

With #ASCO26 just around the corner, it is my great pleasure to present in the oral abstract session, alongside prominent colleagues and chairs, the intracranial efficacy data of #tarlatamab from #DeLLphi-304 trial, the first data on CNS efficacy of a T-cell engager in #SCLC. June 1st, 13:15-16:15, Hall D1

#SoMe #LCSM @SclcSMASHERS
@OncoAlert @OncBrothers
@PeerView @PortalOnconews @MedscapeOnc
@VJOncology @ecancer @LungCancerEu @YoungLungCancer @HeSMO_X @HenryDunantGR

Honoring Dr. Frances Shepherd, as she retires after six decades of advancing lung cancer research and patient care 🫁— a true pioneer, visionary leader, and deeply inspiring physician 🦸‍♀️🏆👸@TonyMok9 @CelineMascaux @karenkellymd

In this episode of Lung Cancer Considered, the @IASLC podcast, I discuss the current treatment considerations for advanced SCLC with Dr. Raffaele Califano and Dr. Jessica Menis. Listen below for the current state of the art! @caliraf @JessicaMenis

iaslc.org/iaslc-news/lun…

Real world analysis of tarlatamab in SCLC (n=27) @JCOPO_ASCO: RR 18%, PFS 5.9m. Signs of CNS activity: in 14pts with brain mets, 2 CR & 1 PR; in 4pts with no baseline mets, none had new CNS mets. C1D1: CRS in 37%, ICANS in 30%. C1D8, CRS 40%, ICANS 16%.

ascopubs.org/doi/10.1200/PO…

Farewell to another productive and exceptionally brainstorming @EORTC LCG meeting under the leadership and guidance of @JordiRemon @HendriksLizza @MarianaBrandao0
Huge 🙏 to Rafal Dziadziusco for a wonder honestly n beautiful Gdansk!!
See you all next year in Athens!!!!

Great discussions at the EORTC Lung Cancer Group meeting in Gdańsk. A real privilege to work with such a collaborative and forward-thinking community—especially encouraging to see new voices actively contributing to study design and research priorities. You are welcome!! #EORTC

Best way to start the @EORTC lung cancer group meeting here in #Gdansk with a fascinating symposium focusing on #SCLC with amazing lectures by @bartolomiej @finn_corinne and @NReguart , including a deep dive in SCLC biology

Fantastic presentation by Prof Jassem about roles of Pharma / Academia in drug development.
The strength of the EORTC Lung Cancer Group lies in its multidisciplinary to design academic studies with drugs developed by pharma aiming to identify optimal drug for groups of patients